Key result
Continuous wearable AI monitoring predicts chemotherapy-induced LVEF decline but requires external validation before clinical adoption.
Why the study?
Chemotherapy-induced cardiotoxicity is a leading cause of morbidity in cancer survivors because conventional surveillance often detects cardiac dysfunction only after significant injury.
Does continuous monitoring with wearable devices and AI improve early detection of subclinical chemotherapy-induced cardiotoxicity in cancer survivors?
Does continuous monitoring with wearable devices and AI improve early detection of subclinical chemotherapy-induced cardiotoxicity in cancer survivors?
A clinical pipeline utilizing wearable devices and AI for continuous monitoring shows promise as an early-warning system for chemotherapy-induced cardiotoxicity, though large-scale validation is required prior to clinical adoption.
Answers are grounded in this paper and cite their sources.
Wearable-AI monitoring for chemotherapy cardiotoxicity remains investigational; leaves open whether prospective trials will confirm clinical utility.
Chemotherapy-induced cardiotoxicity (CIC) is a leading cause of morbidity in cancer survivors, as conventional surveillance often detects cardiac dysfunction only after significant injury. This review moves beyond summarizing emerging technologies to focus on the end-to-end clinical pipeline—from sensor data to actionable decision-making—for creating a proactive “early-warning” system. We examine how continuous monitoring with wearable devices and artificial intelligence (AI) can detect subclinical CIC by analyzing digital biomarkers like heart rate variability. Proof-of-concept studies show AI can predict LVEF decline with moderate to high accuracy, though evidence is limited by small cohorts and lacks external validation. Implementing this wearable-AI pipeline could fill a critical surveillance gap and enable timely cardioprotective interventions. However, large-scale validation and building clinician trust through interpretable models are crucial before routine clinical adoption.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question. Continuous monitoring with wearable AI can predict chemotherapy-induced LVEF decline with moderate to high accuracy, though large-scale external validation is needed before clinical adoption.
Synapse has enriched 10 related papers. Consider them for comparative context: